[go: up one dir, main page]

SMT202000567T1 - Regimi di dosaggio di melflufen per il cancro - Google Patents

Regimi di dosaggio di melflufen per il cancro

Info

Publication number
SMT202000567T1
SMT202000567T1 SM20200567T SMT202000567T SMT202000567T1 SM T202000567 T1 SMT202000567 T1 SM T202000567T1 SM 20200567 T SM20200567 T SM 20200567T SM T202000567 T SMT202000567 T SM T202000567T SM T202000567 T1 SMT202000567 T1 SM T202000567T1
Authority
SM
San Marino
Prior art keywords
cancer
dosage regimens
melflufen
melflufen dosage
regimens
Prior art date
Application number
SM20200567T
Other languages
English (en)
Inventor
Jakob Lindberg
Original Assignee
Oncopeptides AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55177548&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMT202000567(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Oncopeptides AB filed Critical Oncopeptides AB
Publication of SMT202000567T1 publication Critical patent/SMT202000567T1/it

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05Dipeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
SM20200567T 2015-12-01 2016-12-01 Regimi di dosaggio di melflufen per il cancro SMT202000567T1 (it)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1521217.8A GB201521217D0 (en) 2015-12-01 2015-12-01 Dosage regimens
PCT/EP2016/079511 WO2017093443A1 (en) 2015-12-01 2016-12-01 Melflufen dosage regimens for cancer
EP16805792.5A EP3383385B2 (en) 2015-12-01 2016-12-01 Melflufen dosage regimens for cancer

Publications (1)

Publication Number Publication Date
SMT202000567T1 true SMT202000567T1 (it) 2020-11-10

Family

ID=55177548

Family Applications (1)

Application Number Title Priority Date Filing Date
SM20200567T SMT202000567T1 (it) 2015-12-01 2016-12-01 Regimi di dosaggio di melflufen per il cancro

Country Status (27)

Country Link
US (3) US20180369141A1 (it)
EP (3) EP3383385B2 (it)
JP (2) JP6878431B2 (it)
KR (2) KR20210092327A (it)
CN (1) CN108289876A (it)
AU (2) AU2016363591B2 (it)
BR (1) BR112018010012A8 (it)
CA (1) CA3003102C (it)
CY (1) CY1123469T1 (it)
DK (1) DK3383385T4 (it)
ES (1) ES2828033T5 (it)
FI (1) FI3383385T4 (it)
GB (1) GB201521217D0 (it)
HR (1) HRP20201632T4 (it)
HU (1) HUE051525T2 (it)
IL (2) IL259101A (it)
LT (1) LT3383385T (it)
MX (2) MX384724B (it)
PL (1) PL3383385T5 (it)
PT (1) PT3383385T (it)
RS (1) RS60986B2 (it)
RU (2) RU2734930C2 (it)
SG (1) SG11201803551YA (it)
SI (1) SI3383385T2 (it)
SM (1) SMT202000567T1 (it)
WO (1) WO2017093443A1 (it)
ZA (2) ZA201802816B (it)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA53904A (fr) * 2018-10-18 2021-08-25 Oncopeptides Ab Composés contenant du deutérium
WO2020160020A1 (en) * 2019-01-28 2020-08-06 Sanofi Methods of treating multiple myeloma
JP2022527532A (ja) * 2019-04-03 2022-06-02 オンコペプティデス エービー メルフルフェンによるalアミロイドーシスの治療
GB201905477D0 (en) * 2019-04-17 2019-05-29 Oncopeptides Ab Novel formulations
WO2021053185A1 (en) * 2019-09-20 2021-03-25 Oncopeptides Ab Melflufen formulations and their use in the treatment or prophylaxis of osteosarcoma
SE544998C2 (en) * 2021-01-13 2023-02-21 Bkmdcl Ab Peptide conjugates of melphalan for the treatment of cancer
EP4366721A1 (en) * 2021-07-08 2024-05-15 Oncopeptides Innovation AB Melflufen for use in the treatment of multiple myeloma

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0002202D0 (sv) 2000-06-13 2000-06-13 Karolinska Innovations Ab New peptides
HUE037863T2 (hu) * 2011-04-28 2018-09-28 Oncopeptides Ab Citotoxikus dipeptidek liofilizált készítménye
EP2909690B1 (en) 2012-10-22 2017-07-19 Parker Hannifin Manufacturing Sweden AB Joystick for utility vehicles
BR112015009280B1 (pt) * 2012-10-26 2022-05-31 Oncopeptides Ab Preparação farmacêutica liofilizada de melfalana flufenamida, composição e kit de combinação de partes
EA032775B1 (ru) * 2013-04-08 2019-07-31 Берг Ллк Способы лечения злокачественной опухоли с использованием комбинированной терапии с коферментом q10

Also Published As

Publication number Publication date
BR112018010012A2 (pt) 2018-11-21
ZA202102438B (en) 2025-08-27
BR112018010012A8 (pt) 2019-02-26
JP2019501881A (ja) 2019-01-24
PL3383385T5 (pl) 2023-12-18
GB201521217D0 (en) 2016-01-13
ES2828033T3 (es) 2021-05-25
JP6878431B2 (ja) 2021-05-26
IL301019B2 (en) 2025-12-01
RU2018123718A (ru) 2020-01-09
CN108289876A (zh) 2018-07-17
CA3003102A1 (en) 2017-06-08
EP3383385A1 (en) 2018-10-10
EP3383385B2 (en) 2023-09-06
HRP20201632T4 (hr) 2023-11-10
US20180369141A1 (en) 2018-12-27
SI3383385T2 (sl) 2024-01-31
AU2016363591A1 (en) 2018-06-28
EP3383385B1 (en) 2020-07-29
IL259101A (en) 2018-06-28
DK3383385T4 (da) 2023-11-06
IL301019B1 (en) 2025-08-01
US20220047507A1 (en) 2022-02-17
KR20210092327A (ko) 2021-07-23
DK3383385T3 (da) 2020-10-12
LT3383385T (lt) 2020-12-28
HRP20201632T1 (hr) 2021-01-08
NZ742548A (en) 2023-10-27
RS60986B1 (sr) 2020-11-30
IL301019A (en) 2023-05-01
AU2016363591B2 (en) 2020-12-10
JP2021088560A (ja) 2021-06-10
ES2828033T5 (es) 2024-04-04
MX384724B (es) 2025-03-14
CY1123469T1 (el) 2022-03-24
AU2021200436A1 (en) 2021-02-25
RU2020134307A (ru) 2020-11-27
RS60986B2 (sr) 2023-12-29
EP3903777A1 (en) 2021-11-03
KR20180087254A (ko) 2018-08-01
MX2018006706A (es) 2018-08-01
SG11201803551YA (en) 2018-05-30
KR102279629B1 (ko) 2021-07-20
RU2734930C2 (ru) 2020-10-26
RU2018123718A3 (it) 2020-04-02
FI3383385T4 (fi) 2023-11-01
US20250144023A1 (en) 2025-05-08
PL3383385T3 (pl) 2021-05-04
SI3383385T1 (sl) 2020-11-30
CA3003102C (en) 2022-09-13
PT3383385T (pt) 2020-10-26
MX2021008738A (es) 2021-08-24
EP3750534A1 (en) 2020-12-16
HUE051525T2 (hu) 2021-03-01
ZA201802816B (en) 2021-07-28
WO2017093443A1 (en) 2017-06-08

Similar Documents

Publication Publication Date Title
IL254705B (en) Combined treatment for cancer
ZA201702382B (en) Combination therapy for cancer
IL249231A0 (en) Pharmaceutical combinations for cancer treatment
IL301019B2 (en) Malflufen dosage regimens for cancer
IL249898A0 (en) Combined cancer treatment
HUE055109T2 (hu) Adagolási rendek TF elleni antitest és gyógyszer konjugátumaihoz
IL247083A0 (en) dose fgh–18
IL246761A0 (en) Combined cancer treatment
GB201418710D0 (en) Dosage regimen
GB201519734D0 (en) Cancer therapy
IL259097A (en) Combination therapy for cancer
HRP20210383T8 (hr) Kombinirana terapija za rak
GB201617850D0 (en) Dosage regimen
GB201521216D0 (en) Dosage regimen
GB201517643D0 (en) Dosage form for melatonin
GB201610502D0 (en) Dosage regimen
GB201511609D0 (en) Cancer therapy
GB201511121D0 (en) Cancer therapy
GB201511120D0 (en) Cancer therapy
GB201417819D0 (en) Agents for cancer therapy
GB201418708D0 (en) Dosage regimen
GB201400171D0 (en) Dosage regimen